Regeneron Exceeds Q2 Earnings and Revenue Expectations Driven by Dupixent Growth
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter results that exceeded Wall Street expectations, with strong performance driven primarily by its key drug Dupixent. The company's adjusted earnings per share came in at $14.29 compared to the expected $10.58, while revenue reached $4.29 billion versus an estimate of $3.8 billion. This marks a 17% year-over-year increase and reflects robust sales across its portfolio. Global Dupixent net sales rose by 38% year over year to $6.0 billion, with U.S. EYLEA HD sales up 52% to $596 million and global Libtayo sales increasing by 30%. Regeneron also reported a significant increase in revenue from its partnership with Sanofi, which rose 51% to $2.17 billion due largely to Dupixent's performance. The company updated its full-year guidance for 2026, raising adjusted gross margin forecasts and narrowing expense ranges. Regeneron also announced the repayment of a balance owed to Sanofi by quarter-end, which is expected to boost collaboration profits in Q3.
Topics: Dupixent growth earnings pharmaceuticals